Eli Lilly and Company (LLY)

Key Updates

Eli Lilly extended its rally with a 2.33% gain to $1,107.12, marking a 10.33% surge over the past day following exceptional Q4 2025 earnings that significantly exceeded expectations. The stock has now advanced 43.97% over six months and 3.02% year-to-date, consolidating above the $1,080 resistance level that was breached in the previous session. Combined Mounjaro and Zepbound sales of $11.7 billion surpassed estimates by $1.3 billion, while management's 2026 revenue guidance of $80-83 billion exceeded consensus by $2.4-5.4 billion, positioning Lilly to capture market share from rival Novo Nordisk, which projected declining sales for 2026.

Current Trend

Eli Lilly maintains a strong uptrend with the stock advancing 43.97% over the past six months and establishing new all-time highs above $1,100. Year-to-date performance of +3.02% demonstrates sustained momentum entering 2026. The stock has decisively broken through multiple resistance levels: the $1,000 psychological barrier, the $1,040 level that constrained price action in January, and most recently the $1,080 threshold. Current price action at $1,107.12 reflects robust institutional buying following the Q4 earnings beat, with the 10.33% single-day surge representing one of the strongest sessions in recent quarters. Support has established at $1,080, with secondary support at the $1,040 level. The 8.14% five-day gain and 6.30% monthly advance confirm accelerating positive momentum.

Investment Thesis

The investment thesis centers on Eli Lilly's dominant position in the rapidly expanding GLP-1 obesity and diabetes treatment market, supported by exceptional product execution, aggressive manufacturing capacity expansion, and a robust pipeline of next-generation therapies. The company has captured majority market share in the obesity drug market from Novo Nordisk, with Zepbound and Mounjaro demonstrating superior growth trajectories—both products more than doubled sales year-over-year. Lilly's $50+ billion manufacturing investment since 2020 across ten U.S. facilities positions the company to capitalize on surging demand while avoiding tariff exposure. The pipeline includes retatrutide, which achieved 28.7% average body weight loss in Phase 3 trials (exceeding Zepbound's efficacy), and orforglipron, an oral GLP-1 therapy that could expand market accessibility. Strategic partnerships with Nimbus Therapeutics and Arrowhead Pharmaceuticals further diversify the obesity treatment portfolio. Premium valuations (5x market P/S ratio, 3x market P/E ratio) are justified by accelerating revenue growth that outpaces pharmaceutical peers and exceptional profitability metrics across all margin categories.

Thesis Status

The investment thesis has strengthened materially following Q4 results and 2026 guidance. Revenue of $19.3 billion (+43% YoY) exceeded estimates by $1.4 billion, with net income of $6.6 billion and adjusted EPS of $7.54 beating consensus by $0.60. Combined Mounjaro ($7.4B, +110% YoY) and Zepbound ($4.3B, +123% YoY) sales of $11.7 billion surpassed the $10.4 billion estimate, demonstrating sustained demand momentum despite 5% price declines. The 2026 guidance of $80-83 billion revenue (vs. $77.6B consensus) and $33.50-$35.00 EPS (vs. $32.47 consensus) confirms management's confidence in volume acceleration through the second half of 2026. The competitive landscape has shifted decisively in Lilly's favor, with Novo Nordisk projecting sales and profit declines for 2026 due to pricing pressures and patent expirations. The Pennsylvania facility announcement ($3.5B investment, operational 2031) ensures long-term supply security for retatrutide, while the November Trump administration deal provides three-year tariff exemption in exchange for discounted Medicare/Medicaid pricing. All thesis pillars—market leadership, manufacturing scale, pipeline depth, and competitive positioning—remain intact and reinforced.

Key Drivers

Q4 2025 results demonstrate exceptional operational execution: total sales increased 43% to $19.3 billion (vs. $17.9B estimate), driven by 46% volume growth despite 5% pricing headwinds, with net income rising to $6.6 billion from $4.4 billion year-over-year (source). Combined GLP-1 franchise sales of $11.7 billion exceeded estimates by $1.3 billion, with Mounjaro generating $7.4 billion (+110% YoY) and Zepbound recording $4.3 billion (+123% YoY) (source). Management issued 2026 guidance of $80-83 billion revenue and $33.50-$35.00 EPS, exceeding consensus estimates of $77.6 billion and $32.47 per share, contrasting sharply with Novo Nordisk's projected sales decline (source). The $3.5 billion Pennsylvania manufacturing facility represents the fourth U.S. site announcement since February 2025 and will produce retatrutide, which demonstrated 28.7% average body weight loss at 68 weeks in Phase 3 trials, exceeding current Zepbound efficacy (source). The facility will create 850 permanent jobs and 2,000 construction positions, with operations beginning in 2031 and each invested dollar generating up to four dollars in local economic activity (source).

Technical Analysis

Eli Lilly trades at $1,107.12, establishing new all-time highs following a 10.33% single-day surge that decisively broke through the $1,080 resistance level. The stock has advanced 8.14% over five days and 6.30% over one month, confirming strong momentum continuation. Year-to-date performance of +3.02% demonstrates sustained buying pressure entering 2026, while the six-month gain of 43.97% reflects the longer-term uptrend trajectory. Immediate support has established at $1,080, representing the previous resistance level that now serves as a floor. Secondary support exists at $1,040, which constrained price action throughout January before the earnings breakout. The $1,000 psychological level provides tertiary support. Volume patterns indicate institutional accumulation, with the earnings-driven rally accompanied by above-average trading activity. The stock's ability to maintain gains above $1,100 will be critical for establishing this level as a new base for further appreciation. Near-term resistance may emerge at $1,150, representing a round-number psychological level and approximately 4% above current prices.

Bull Case

• Combined Mounjaro and Zepbound sales of $11.7 billion exceeded estimates by $1.3 billion, with both products more than doubling year-over-year (Mounjaro +110%, Zepbound +123%), demonstrating sustained demand momentum and market share capture from Novo Nordisk in the rapidly expanding GLP-1 market (source)
• 2026 revenue guidance of $80-83 billion exceeds consensus estimates by $2.4-5.4 billion, with adjusted EPS guidance of $33.50-$35.00 surpassing the $32.47 consensus, while competitor Novo Nordisk projects declining sales and profits for 2026, creating a significant competitive advantage (source)
• $50+ billion manufacturing capacity expansion across ten U.S. facilities since 2020, including the newly announced $3.5 billion Pennsylvania plant for next-generation therapies, ensures supply security to meet surging demand while avoiding tariff exposure through domestic production (source)
• Retatrutide pipeline demonstrates 28.7% average body weight loss at 68 weeks in Phase 3 trials, exceeding current Zepbound efficacy and positioning Lilly to maintain therapeutic leadership with differentiated products targeting various patient populations when the Pennsylvania facility becomes operational in 2031 (source)
• Q4 2025 revenue of $19.3 billion (+43% YoY) was driven by 46% volume growth despite 5% pricing headwinds, with management indicating volume acceleration expected in the second half of 2026, demonstrating the company's ability to drive growth through market expansion rather than price increases (source)

Bear Case

• Q4 results showed 5% price declines with management indicating pricing will decline further in early 2026 due to the November Trump administration deal requiring discounted Medicare/Medicaid pricing, potentially compressing margins despite volume growth expectations (source)
• Premium valuation multiples of approximately 5x the market's P/S ratio and nearly 3x its P/E ratio leave limited room for multiple expansion and increase vulnerability to any execution missteps or competitive threats in the GLP-1 market (source)
• FDA delayed approval of oral weight-loss pill orforglipron in January 2026, creating uncertainty around the timeline for market entry of this critical convenience-driven product that could expand patient accessibility beyond injectable therapies (source)
• Pennsylvania manufacturing facility will not become operational until 2031, creating a six-year gap before next-generation retatrutide production capacity comes online, potentially limiting supply flexibility if demand exceeds current facility capacity before then (source)
• Partnerships with Arrowhead Pharmaceuticals and Nimbus Therapeutics involve significant milestone payments (up to $1.3 billion for Nimbus alone) and royalty commitments that could pressure margins if these combination therapies or next-generation oral treatments achieve commercial success (source)